38.62
-0.45 (-1.15%)
| Penutupan Terdahulu | 39.07 |
| Buka | 39.20 |
| Jumlah Dagangan | 2,446,371 |
| Purata Dagangan (3B) | 766,249 |
| Modal Pasaran | 1,734,126,976 |
| Harga / Pendapatan (P/E TTM) | 5.04 |
| Harga / Buku (P/B) | 4.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -2.20 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.05% |
| Nisbah Semasa (MRQ) | 23.31 |
| Aliran Tunai Operasi (OCF TTM) | -66.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -42.10 M |
| Pulangan Atas Aset (ROA TTM) | -31.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -48.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | MBX Biosciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.25 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 3.12% |
| % Dimiliki oleh Institusi | 106.60% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Nea Management Company, Llc | 30 Sep 2025 | 3,614,486 |
| Nvp Associates, Llc | 30 Sep 2025 | 2,136,335 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 2,123,604 |
| Kynam Capital Management, Lp | 30 Sep 2025 | 2,000,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 88.00 (Guggenheim, 127.86%) | Beli |
| Median | 60.00 (55.36%) | |
| Rendah | 18.00 (Goldman Sachs, -53.39%) | Jual |
| Purata | 56.40 (46.04%) | |
| Jumlah | 4 Beli, 1 Jual | |
| Harga Purata @ Panggilan | 33.97 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 28 Jan 2026 | 66.00 (70.90%) | Beli | 35.83 |
| Guggenheim | 16 Jan 2026 | 88.00 (127.86%) | Beli | 40.53 |
| 10 Nov 2025 | 77.00 (99.38%) | Beli | 24.49 | |
| UBS | 07 Jan 2026 | 60.00 (55.36%) | Beli | 32.55 |
| Stifel | 19 Dec 2025 | 50.00 (29.47%) | Beli | 30.42 |
| Goldman Sachs | 04 Dec 2025 | 18.00 (-53.39%) | Jual | 30.54 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 22 Jan 2026 | Pengumuman | MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair |
| 11 Jan 2026 | Pengumuman | MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference |
| 15 Dec 2025 | Pengumuman | MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 |
| 18 Nov 2025 | Pengumuman | MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference |
| 06 Nov 2025 | Pengumuman | MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |